Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15043
|
| Title: | Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer |
| Authors: | Yoshino, T;Cervantes, A;Bando, H;Martinelli, E;Oki, E;Xu, RH;Mulansari, NA;Govind Babu, K;Lee, MA;Tan, CK;Cornelio, G;Chong, DQ;Chen, LT;Tanasanvimon, S;Prasongsook, N;Yeh, KH;Chua, C;Sacdalan, MD;Sow Jenson, WJ;Kim, ST;Chacko, RT;Syaiful, RA;Zhang, SZ;Curigliano, G;Mishima, S;Nakamura, Y;Ebi, H;Sunakawa, Y;Takahashi, M;Baba, E;Peters, S;Ishioka, C;Pentheroudakis, G |
| Contributors: | National Institute of Cancer Research |
| Abstract: | The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries. |
| Date: | 2023-05-24 |
| Relation: | ESMO Open. 2023 May 24;8(3):Article number 101558. |
| Link to: | http://dx.doi.org/10.1016/j.esmoop.2023.101558 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2059-7029&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001017663500001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160253356 |
| Appears in Collections: | [陳立宗] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB37236086.pdf | | 721Kb | Adobe PDF | 176 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
